Recombinant SARS-CoV-2 Spike S1 antibody (RBD)

Catalog No. ABIN6953152

Product Details anti-SARS-CoV-2 Spike S1 Antibody

Target: SARS-CoV-2 Spike S1

Antibody Type: Recombinant Antibody

Fragment: single-domain Antibody (sdAb)

Binding Specificity: RBD

Reactivity: SARS Coronavirus-2 (SARS-CoV-2)

Host: Human

Clonality: Monoclonal

Conjugate: This SARS-CoV-2 Spike S1 antibody is un-conjugated

Application: ELISA, Neutralization (Neut), Colloidal Gold Immunochromatography Assay (GICA)

Characteristics: This SARS-CoV-2 Spike RBD Nanobody is a recombinant monoclonal antibody generated through the expression of a DNA sequence inserting a human IgG1 Fc domain at the C-terminus, in human embryonic kidney 293 cells (HEK293). The DNA sequence encodes the SARS-CoV-2 spike receptor-binding domain (RBD). The antibody is purified by protein G in vitro. It has been validated with high reactivity towards SARS-CoV-2-S1-RBD by a functional ELISA and good sensitivity for human SARS-CoV-2 spike glycoprotein (S protein) via the Colloidal Gold Immunochromatography Assay (GICA). In neutralization assay, the binding signal of SARS-CoV-2 Spike RBD Nanobody was inhibited by ACE2 protein-HRP conjugated inhibitor, with a 0.1074 μg/mL IC50. Specifically binding and recognizing the RBD of the SARS-CoV-2 spike glycoprotein (S protein), so the SARS-CoV-2 Spike RBD Nanobody can react with samples infected with human coronavirus SARS-CoV-2. But it does not respond to MERS or SARS-CoV spike protein. Akin to other nanobodies, this recombinant nanobody is small and stable, which allows for its reaching to hidden epitopes such as crevices of target proteins.
VHH fusion with human IgG1 Fc

Purification: affinity-chromatography

Immunogen: Recombinant Human Novel Coronavirus Spike glycoprotein(S) (319-541aa)

Clone: A1

Isotype: IgG1

Application Details

Application Notes: ELISA 1:10000-1:100000
GICA 1:10000-1:40000
Neutralising 1:100-1:10000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: 50 % Glycerol, 0.01M PBS, pH 7.4, 0.03 % Proclin 300

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze

Target Details for SARS-CoV-2 Spike S1

Target: SARS-CoV-2 Spike S1

Abstract: SARS-CoV-2 Spike S1 Products

Synonyms: E2 antibody, Surface Glycoprotein antibody, S antibody

Target Type: Viral Protein

Background: Spike glycoprotein comprises two functional subunits responsible for binding to the host cell receptor (S1 subunit) and fusion of the viral and cellular membranes (S2 subunit). For many coronavirus (CoVs), S is cleaved at the boundary between the S1 and S2 subunits, which remain non-covalently bound in the prefusion conformation. The distal S1 subunit comprises the receptor-binding domain(s) and contributes to stabilization of the prefusion state of the membrane-anchored S2 subunit that contains the fusion machinery. S is further cleaved by host proteases at the so-called S2' site located immediately upstream of the fusion peptide in all CoVs. This cleavage has been proposed to activate the protein for membrane fusion via extensive irreversible conformational changes. However, different CoVs use distinct domains within the S1 subunit to recognize a variety of attachment and entry receptors, depending on the viral species. Endemic human coronaviruses OC43 and HKU1 attach via their S domain A to 5-N-acetyl-9-O-acetyl-sialosides found on glycoproteins and glycolipids at the host cell surface to enable entry into susceptible cells. MERS-CoV S uses domain A to recognize non-acetylated sialoside attachment receptors, which likely promote subsequent binding of domain B to the entry receptor, dipeptidyl-peptidase 4. SARS-CoV and several SARS-related coronaviruses (SARSr-CoV) interact directly with angiotensin-converting enzyme 2 (ACE2) via SB to enter target cells.

Gene ID: 43740568

UniProt: P0DTC2